Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Medicine of the Future—The Transformation from Reactive to Proactive (P4) Med...Ryan Squire
Medicine of the Future—The Transformation from Reactive to Proactive (P4) Medicine as presented at the Ohio State University Medical Center Personalized Health Care National Conference.
Leroy Hood, MD, PhD, is the president and founder of the Institute of Systems Biology. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. His professional career began at Caltech where he and his colleagues pioneered four instruments — the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer — which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer played a crucial role in contributing to the successful mapping of the human genome during the 1990s.
http://www.systemsbiology.org/Scientists_and_Research
Death prompts a review of gene therapy vectorLindsay Meyer
Case study and analysis of Targeted Genetics' adeno-associated virus, tgAAC94. Includes overview of clinical trial design, FDA action, NIH investigation, and outcomes surrounding the death of a patient enrolled in the investigational trial.
Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Medicine of the Future—The Transformation from Reactive to Proactive (P4) Med...Ryan Squire
Medicine of the Future—The Transformation from Reactive to Proactive (P4) Medicine as presented at the Ohio State University Medical Center Personalized Health Care National Conference.
Leroy Hood, MD, PhD, is the president and founder of the Institute of Systems Biology. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. His professional career began at Caltech where he and his colleagues pioneered four instruments — the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer — which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer played a crucial role in contributing to the successful mapping of the human genome during the 1990s.
http://www.systemsbiology.org/Scientists_and_Research
Death prompts a review of gene therapy vectorLindsay Meyer
Case study and analysis of Targeted Genetics' adeno-associated virus, tgAAC94. Includes overview of clinical trial design, FDA action, NIH investigation, and outcomes surrounding the death of a patient enrolled in the investigational trial.
Trichomoniasis in Pregnancy - Clinical Education for ProvidersReproductiveHealth
This case-based curriculum is the product of an expert consensus meeting convened to identify practice gaps in STI management and offers guidance beyond the CDC’s STD treatment guidelines. This presentation highlights the case of Carly, a 28-year-old woman, G3 P1102, who is 30 weeks pregnant. She presents at her routine prenatal visit reporting malodorous discharge and mild vaginal irritation. Review this case to get the latest expert guidance on best practices in trichomoniasis screening and treatment.
For more evidence-based, peer reviewed slides on reproductive health topics, visit www.arhp.org/CORE. Review a free, on-demand webinar on managing prevalent & problematic STIs and earn CME at www.arhp.org/STIwebinar.
The Fauci/COVID-19 Dossier
This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support
of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CCBY-NC-SA
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
London & Partners MedCity Cell & Gene Therapy Report londonandpartners
The golden triangle & Japan, natural collaborators in cell and gene therapy. Discover Cambridge, London and Oxford’s thriving life sciences ecosystem and cell and gene therapy expertise. The golden triangle offers clinical trials capabilities, a diverse population and single healthcare system, all supported by a committed government. Collaborate with us and help develop the next generation of cell and gene therapy treatments.
Improved outcomes after intratumoral administration of immunostimulatory mRNA...ModernaTherapeutics1
4th International mRNA Health Conference – November 1, 2016
Boston, MA
Improved outcomes after intratumoral administration of immunostimulatory mRNA in a novel cationic lipid
A New Frontier of Precision Medicine: Using PET for Image-Guided Neurointerve...InsideScientific
Mice are by far the most frequently used animal for modeling disease and developing therapeutic strategies including neurointerventions. However, due to its anatomical and physiological barriers, the brain is a difficult target for delivery of therapeutic agents. Systemic administration is plagued with marginal brain accumulation and high risk of off-target side effects.
In this webinar sponsored by Scintica Instrumentation, Dr. Piotr Walczak, Dr. Mirosław Janowski and Dr. Wojciech Lesniak address this challenge and discuss why advanced imaging is essential to perform image-guided neurointerventions.
First, Dr. Janowski provides rationale as to how imaging can be used to better understand how therapeutic agents are delivered to the brain and subsequently cleared. Next, Dr. Walczak reviews methodological and technological advances for improving precision and reproducibility of brain targeting in mice based on MRI and two-photon microscopy. Finally, Dr. Lesniak presents recently-published results using ARGUS PET/CT to quantify intra-artrial delivery of antibodies, nanobodies and poly(amidoamine) dendrimers.
Key Topics Include:
- Overview of Pre-Clinical PET/CT imaging
- Examples from applications including oncology, neurology, cardiology and dynamic imaging
- An introduction to SuperArgus PET/CT and what makes it unique
To learn more, go to:
https://insidescientific.com/webinar/precision-medicine-using-pet-image-guided-neurointervention/
This is Second Edition of Compendium of selected cases for the
educational purposes of the medical
technologists, residents in pathology,
pathologists, oncologists, and clinical
chemists
Trichomoniasis in Pregnancy - Clinical Education for ProvidersReproductiveHealth
This case-based curriculum is the product of an expert consensus meeting convened to identify practice gaps in STI management and offers guidance beyond the CDC’s STD treatment guidelines. This presentation highlights the case of Carly, a 28-year-old woman, G3 P1102, who is 30 weeks pregnant. She presents at her routine prenatal visit reporting malodorous discharge and mild vaginal irritation. Review this case to get the latest expert guidance on best practices in trichomoniasis screening and treatment.
For more evidence-based, peer reviewed slides on reproductive health topics, visit www.arhp.org/CORE. Review a free, on-demand webinar on managing prevalent & problematic STIs and earn CME at www.arhp.org/STIwebinar.
The Fauci/COVID-19 Dossier
This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support
of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CCBY-NC-SA
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
London & Partners MedCity Cell & Gene Therapy Report londonandpartners
The golden triangle & Japan, natural collaborators in cell and gene therapy. Discover Cambridge, London and Oxford’s thriving life sciences ecosystem and cell and gene therapy expertise. The golden triangle offers clinical trials capabilities, a diverse population and single healthcare system, all supported by a committed government. Collaborate with us and help develop the next generation of cell and gene therapy treatments.
Improved outcomes after intratumoral administration of immunostimulatory mRNA...ModernaTherapeutics1
4th International mRNA Health Conference – November 1, 2016
Boston, MA
Improved outcomes after intratumoral administration of immunostimulatory mRNA in a novel cationic lipid
A New Frontier of Precision Medicine: Using PET for Image-Guided Neurointerve...InsideScientific
Mice are by far the most frequently used animal for modeling disease and developing therapeutic strategies including neurointerventions. However, due to its anatomical and physiological barriers, the brain is a difficult target for delivery of therapeutic agents. Systemic administration is plagued with marginal brain accumulation and high risk of off-target side effects.
In this webinar sponsored by Scintica Instrumentation, Dr. Piotr Walczak, Dr. Mirosław Janowski and Dr. Wojciech Lesniak address this challenge and discuss why advanced imaging is essential to perform image-guided neurointerventions.
First, Dr. Janowski provides rationale as to how imaging can be used to better understand how therapeutic agents are delivered to the brain and subsequently cleared. Next, Dr. Walczak reviews methodological and technological advances for improving precision and reproducibility of brain targeting in mice based on MRI and two-photon microscopy. Finally, Dr. Lesniak presents recently-published results using ARGUS PET/CT to quantify intra-artrial delivery of antibodies, nanobodies and poly(amidoamine) dendrimers.
Key Topics Include:
- Overview of Pre-Clinical PET/CT imaging
- Examples from applications including oncology, neurology, cardiology and dynamic imaging
- An introduction to SuperArgus PET/CT and what makes it unique
To learn more, go to:
https://insidescientific.com/webinar/precision-medicine-using-pet-image-guided-neurointervention/
This is Second Edition of Compendium of selected cases for the
educational purposes of the medical
technologists, residents in pathology,
pathologists, oncologists, and clinical
chemists
Prospects and Problems of Development of Candidate Vaccine against COVID 19ijtsrd
There is an urgent need to develop a vaccine against coronavirus disease 2019 COVID 19 , which is caused by a new coronavirus, severe acute respiratory syndrome coronavirus type 2 SARS CoV 2 infection. Although vaccine development typically requires 3 to 5 years, there is a possibility that the vaccine developed for either severe acute respiratory syndrome SARS or the middle east respiratory syndrome MERS could be used against COVID 19 as well. Therefore, a vaccine against COVID 19 is expected to be commercialized within 1 to 2 years. If so, it will be the fastest vaccine development in human history.In this review, we have summarized the information released as of April 10, 2020. Takuma Hayashi | Yasuaki Amano | Takashi Ura | Ikuo Konishi "Prospects and Problems of Development of Candidate Vaccine against COVID-19" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-2 , February 2021, URL: https://www.ijtsrd.com/papers/ijtsrd38521.pdf Paper Url: https://www.ijtsrd.com/medicine/other/38521/prospects-and-problems-of-development-of-candidate-vaccine-against-covid19/takuma-hayashi
: The COVID-19 pandemic is spreading across the globe at an alarming rate. Corona Virus is a large
family of positive-sense, single-stranded Ribo Nuclic Acid(RNA) viruses that belong to the Nidovirales order. It
was first started in Wuhan, Hubei Province, China and then subsequently spread to dozens of other countries
becoming a global pandemic. COVID-19 manifests with a wide clinical spectrum ranging from asymptomatic
patients to septic shock and multi organ dysfunction. The most common symptoms of patients include fever (98.
6%), fatigue (69.6%), dry cough, and diarrhea. The WHO recommends collecting samples from both the upper
and lower respiratory tracts. This can be achieved through expectorated sputum, broncho-alveolar lavage or
endotrachial aspirate, These samples are then assessed for viral RNA using polymerase chain reaction(PCR).
Patients with pre-existing co-morbidities have a higher case fatality rate. These co-morbidities include diabetes (7.
3%), respiratory disease(6.5%), cardiovascular disease(10.5%), hypertension(6%) and malignncy(5.6%). Patients
without co-morbidities have a lower case fatality rate(0.9%). Preventive measures must focus on optimizing
infection control protocols, self-isolation, and patient isolation during the provision of clinical care. No confirmed
medication or vaccine has been developed. Current treatment strategies are aimed at symptomatic care and
oxygen therapy. Chloroquine phosphate and lopinavir/ritonavir have been suggested. Other suggested anti-virals
include ribavirin and abidor. Usage of personal protective equipment, washing hands, sanitization, social distance
and general awareness can stop transmission of virus. Prophylactic vaccination is required for the future
prevention of COV-related epidemic or pandemic.
תשובה לעתירה של חברת נמלי ישראל שנמחקה _ תשובה מיום 30092021 www.epidella.com
מדוע רוצים להרחיב את המעגנות בישראל ובקישון בפרט?
איך זה מתחבר לתכנית המתחמים הלוגיסטיים? בתגובתי לעתירה של חברת נמלי ישראל שבינתיים נמחקה, השבתי על הקשר בין התכניות.
אלה נווה
יצא למשרד הבריאות בהליך של מיצוי הליכים היום, ביחד עם נספחים ": מצגת על הניסוי האוטומטי בילדים, מצגת על "קודם אל תזיק" קובץ של גירט ונדן בוש, וקובץ של נערים וילדים שמתו בארה"ב לאחר התרכיב
כמדווח במערכת ה VAERS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
ד"ר ג'סיקה רוז מכתב על ילדים בני 12 עד 18 ניתוח נתוני VAERS
1. 1
Potential dangers associated with COVID-19 injectable products for children aged 12-18
Jessica Rose, PhD, MSc, BSc
May 30, 2021
Neither the Pfizer/BioNTech nor the Moderna COVID-19 products have been approved or licensed by the U.S.
Food and Drug Administration (FDA), having been authorized instead for emergency use by FDA under an
Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16
years of age and older. [1,2,3]
The precautionary principle promotes transparency and the adoption of preventative measures to address adverse
events (AEs) as risks to the public. It is vital that individuals are informed of potential risks before agreeing to
participate in any medically-involved treatment program such as the roll-out of the Pfizer/BioNTech and Moderna
products into the U.S. adult population and plans of continuing this roll-out into the juvenile population in May 2021.1
1. TOTAL adverse event reports made in the context of COVID-19 products are atypically high
Adverse event reports are currently at 252,523 (U.S. VAERS) and this number is increasing at an exponential rate.
There are already FOUR TIMES AS MANY total reports as of May 28th
, 2021 (Figure 1, right) than for the ENTIRETY of
the VAERS reports collected from last year.
Figure 1: Time series plots showing VAERS reports by year with trendline in blue (left) and showing cumulative
VAERS reports associated with the COVID-19 products for the year 2021 (right). Data contains VAERS reports
processed as of 5/28/2021.
1.1 Children aged 12-18 are experiencing severe adverse events with CARDIOVASCULAR AEs occuring in 17%
of this subpopulation
Children aged 12-18 comprise 3.4% of the total VAERS population with 58% comprising females. Of these 8500
children, 9 (0.1%) have died, 846 (10%) have experienced a severe adverse event resulting in hospitalization or
debilitation. 1463 (17%) have experienced cardiovascular AEs, 437 (5.1%) have experienced a neurological AE and
928 (11%) have experienced an immunological AE. 26 (0.3%) of the young women in this subset have experienced
female reporductive issues. 18 (0.2%) have succumbed to a breakthrough COVID-19 infection and none have died
from a breakthrough infection to date.
1 The National Childhood Vaccine Injury Act of 1986 (NCVIA) requires health care providers and vaccine manufacturers to report to the DHHS
specific adverse events following the administration of those vaccines outlined in the Act.[1]
2. 2
Figure 3: Histograms showing distributions of categorized AEs by age.
Figure 3 shows the distributions of each AE category by age. The data is skewed toward the upper range of the age
set and this is statistically significant (I>1). It appears from this data that young people over the age of 15 are
experiencing and reporting AEs at significantly higher rates (p<0.001) than their younger counterparts. What is truly
striking are the high number of reports of cardiovascular AEs. Children are not at high risk for cardiovascular
ailments2
, but appear to be at risk in the context of these COVID-19 injections.
1.2 The injections are likely causing the AEs
Reporting AEs that occur in temporal proximity to injection of biological material into humans is critical and serves
as an early warning system for adverse events not detected during pre-market testing of such products.[4] It is
especially relevant in the context of technologically novel treatments in the experimental phase of development such
as the Pfizer/BioNTech mRNA injectables.
Figure 4: Plots showing percentages of VAERS IDs as per cardiovascular, neurological and immunological AEs and
the total SAEs and Female Reproductive Issues against the number of days following injection.
2 https://www.cdc.gov/heartdisease/heart_attack.htm
Observed
Expected 5.0%/day (p<<0.001)
Observed
Expected 6.5%/day (p<<0.001)
Observed
Expected 4.8%/day (p<<0.001)
Observed
Expected 4.1%/day (p<<0.001)
Observed
Expected 6.9%/day (p=0.9)
3. 3
Analysis of adverse event data suggests that these products are likely the cause of female reproductive issues, the
breakthrough infections and the cardiovascular, neurological and immunological AEs.3
What is striking is the
extremely high percentages of reports made within 24 hours of the injections in the cardiovascular, neurological and
immunological AE categories. In each case, over 80% of events occurred and reports filed on the same day of the
injections.
Th be clear, a causal effect means that a change in one variable leads to change in another variable. If the
cardiovascular AEs, for example, following COVID-19 injections are not causally-linked, then the reported percentages
of these AEs should be equally distributed across days following injection: there should not be an excess of reports
on days 0, 1 and 2, yet there are. Chi-square tests confirm association for each AE group with p-values less than 0.001
in each case. If risk is not accentuated by some immediate factor temporally, then that risk should necessarily plateau
or diminish each day.
The null hypothesis holds that in the absence of causality, the distributions of AE reports should be even about the
y-axis: there is an equal chance of the event occurring at any point following, or even before, the injection date. This
is not the case and thus the null hypothesis is negated. The evidence for causation in this data is strong and in addition
to this evidence, the Bradford Hill Criteria are satisfied.4
2. The potential disruption of the Renin-Angiotensin-Aldosterone System
Messenger RNA (mRNA) platforms are new in medical microbiology and have never before been implemented for
use in human subjects on a global scale in the context of viruses. mRNA stands for messenger RNA and is the coding
template for a protein. All living things use it for production of these building blocks of life. In the context of the
Pfizer/BioNTech and Moderna products, the mRNA encoding the pre-fusion spike protein, which is the protein on
the surface of the coronavirus that is used for binding and infection of host cells, is wrapped in a lipid-nanoparticle
(LNP) shell to enable stable introduction to host cells via intramuscular injection. It is currently not known how long
the mRNA remains for the purpose of production and presentation of spike proteins to specialized cells to induce a
specific immune response against them. The protein on the surfaces of human cells that the spike protein binds to
in order to infect the cell is called Angiotensin Converting Enzyme-2 (ACE-2). ACE-2 is an enzyme that acts to regulate
the Renin-Angiotensin Aldosterone System (RAAS) to decrease blood pressure to normal levels are to maintain
electrolyte levels at normal-functioning values, and can act in both membrane-bound and soluble forms. This protein
is commonly expressed in many cell types distributed all over the body and is primarily associated with enterocytes
which are specialized cells in the epithelium.5
It is an essential component of the RAAS: an essential system in every
human being. In the presence of SARS-nCoV-2 virions (viral particles), it is known that the binding sites of ACE-2
proteins are occupied by the SARS-nCoV-2 viral particle via the spike protein. This can result in dysregulation of the
RAAS which would clinically manifest as hypertensive disorders, fibrosis or problems with any one of the organs
involved with the system and/or the arteries.[56] These problems are matching the AEs that are being reported at
record rates.
There is increased activity of the RAAS in infancy and childhood.[6] The effects of both SARS-nCoV-2 and the spike
protein as an injectable immune system stimulant, on the RAAS, are currently being investigated. It has been shown
that the presence of SARS-nCoV-2 and the spike protein on its own induce ACE-2 expression downregulation and
cause damage to vascular endothelial cells.[56] This means ACE-2 is less prominent on the surfaces of cells and
subsequently, less prominent in soluble form. This downregulation of ACE-2 naturally means is that there are fewer
binding sites to occupy with respect to ACE-2, both in membrane-bound and soluble forms of the protein. In the
presence of a protein, like the spike protein, that binds ACE-2 with high affinity (very strongly), it is easy to envision
competitive inhibition for binding sites arising. Thus, in the presence of high levels of spike proteins, even fewer ACE-
3 A study of the U.S. Vaccine Adverse Events Reporting System (VAERS) of the COVID-19 Messenger ribonucleic acid (mRNA) biologicals. Dr.
Jessica Rose. Science, Public Health Policy, and The Law. Volume 2:59–80, May, 2021, Clinical and Translational Research
4 The Bradford Hill criteria, otherwise known as Hill's criteria for causation, are a group of nine principles that can be useful in establishing
epidemiologic evidence of a causal relationship between a presumed cause and an observed effect and have been widely used in public health
research. They were established in 1965 by the English epidemiologist Sir Austin Bradford Hill.
5 A thin, continuous, protective layer of cells that line the outer surfaces of organs and blood vessels throughout the body, as well as the inner
surfaces of cavities in many internal organs. Wikipedia reference.
4. 4
2 binding sites would be available to exert their inherent purpose and subsequently, an overactive RAAS would ensue
accompanied by fibrosis in many sites. In individuals who already have an overactive RAAS, such as many of our
elderly with clinical manifestations of hypertension, the obese and pregnant women and children [6,57,58,59], this
would result in an even more overactive RAAS due to the enhanced lack of readily-available ACE-2 to close the RAAS
loop. The spike protein alone can also impair Nitric Oxide (NO) bioavailability and inhibit mitochondrial function.[56]
It is interesting that children are not suffering serious pathologies or death and this is likely due to robust and healthy
innate immune responses as part of a balanced and fully-functioning immune system. This would result in a low viral
burden and thus less ACE-2 binding due to infrequency of SARS-nCoV-2 spike protein and thus no serious clinical
complications both in the context of the infection and in the context of the RAAS. The take home message on this
point is that further studies are required prior to further experimentation in the human population. We simply do
not know enough on this particular subject yet.
3. We inherently have effective natural host defenses!!
Effective antiviral responses against the SARS-nCoV-2 virus in the form of both cellular and humoral immune
responses have been reported in peer-reviewed studies.[39-44] Because of the combination of a low Infection
Fatality Rate (IFR) of 0.15% indicating effective and robust immune responses, it remains unclear why multiple
experimental mRNA vaccines have been fast-tracked through conventional testing protocols and are currently being
fast-tracked through production and administration into the public. What is even more unclear is why these products
are being pushed into young demographics since these demographics do not suffer serious pathologies from COVID-
19, as a general rule. The mortality rate from COVID-19 in children 17 and under is 0.06%, as per the CDC reports.
With repurposed drugs like Chloroquine and Ivermectin showing extremely positive results in patients [20-30], it is
also unclear why these drugs are not being more extensively promoted as effective tools in the fight against this virus.
One looming possibility is that EUA is not permissible if FDA-recognized effective treatments exist. Newer to the
market of COVID-19 treatments are Nitric Oxide products shown to be 100% effective at reducing viral burden.6
[54,
55]
A healthy immune system is the best weapon we have against pathogenic organisms. It is vital that the public is made
aware that the immune system cannot function optimally in the context of Vitamin D deficiency so it is recommended
to check Vitamin D levels regularly, especially if you live in sun-deprived climate, and to supplement when necessary.
A vitamin D level of 20 ng/mL or higher is considered to be a non-deficient level.[7]
Functioning and balanced systems are essential to health and this should be highly promoted by governing agencies,
both as a rule of thumb, and especially in the context of a pathogen that we know uses the ACE-2 protein as receptor
to bind and enter host cells to infect them. In the context of a balanced and functioning immune system and RAAS
system, SARS-nCoV-2 does not impose a threat to the majority of humans. One way to ensure a disease state is to
maintain a chronic imbalance in any one of these essential systems. One way to potentially induce an imbalance in
the RAAS is by saturating it with a protein that binds one of its essential components. It is very concerning to me that
millions of individuals have already had the coding material for the SARS-nCoV-2 spike protein injected into their
bodies. The implications for the RAAS, even in individuals with functioning and balanced RAAS, are potentially serious
and unknown at this point in time. It is imperative that further studies on the relationship between the spike protein
and the RAAS are completed before any further roll-outs continue. The implications in the context of pathogenic
priming are also serious and this also requires further study prior to advancement of any roll-out of these products.
Safety is always a point of relevance with regards to new biological agents. Considering that no long-term studies
were completed prior to the global-roll of these products, and the exponential rise of AEs, safety is certainly being
called into question.
Also considering the fact that children are not in a high-risk group with regards to mortality, epidemiological and
immunological evidence, there is absolutely no reason to put children at risk. These data clearly point to risk and
again, this is VERY early data.
6 See Bellerophon Therapeutics and Vero Biotech
5. 5
References
1. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html
2. Temporary_Authorisation_Patient_Information_BNT162_7_0_UK.pdf
3. Fact Sheet for Vaccination Providers-Full EUA PI_Final_2.25.2021.pdf
4. VAERSDataUseGuide_November2020
5. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-
19 via autoimmunity. J Transl Autoimmun. 2020 Apr 9;3:100051. doi: 10.1016/j.jtauto.2020.100051. PMID:
32292901; PMCID: PMC7142689.
6. Dillon MJ. Renin-angiotensin-aldosterone system. Eur J Clin Pharmacol. 1980 Jul;18(1):105-8. doi:
10.1007/BF00561486. PMID: 6249611.
7. JoAnn E. Manson, M.D., Dr.P.H., Patsy M. Brannon, Ph.D., R.D., Clifford J. Rosen, M.D., and Christine L.
Taylor, Ph.D. Vitamin D Deficiency — Is There Really a Pandemic? New England Journal of Medicine
8. Noa Dagan, M.D., et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New
England Journal of Medicine. February 24, 2021, DOI: 10.1056/NEJMoa2101765
9. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev.
2019 Mar 13;32(2):e00084-18. doi: 10.1128/CMR.00084-18. PMID: 30867162; PMCID: PMC6431125.
10. Nath TR, Malaviya AN, Kumar R, Balakrishnan K, Singh BP. A study of the efficacy of typhoid vaccine in
inducing humoral and cell-mediated immune responses in human volunteers. Clin Exp Immunol.
1977;30(1):38-43.
11. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B. Field evaluation of vaccine
efficacy. Bull World Health Organ. 1985;63(6):1055-68. PMID: 3879673; PMCID: PMC2536484.
12. Furman D, Davis MM. New approaches to understanding the immune response to vaccination and infection.
Vaccine. 2015 Sep 29;33(40):5271-81. doi: 10.1016/j.vaccine.2015.06.117. Epub 2015 Jul 29. PMID:
26232539; PMCID: PMC4581990.
13. Demeure CE, Derbise A, Guillas C, Gerke C, Cauchemez S, Carniel E, Pizarro-Cerdá J. Humoral and cellular
immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Vaccine. 2019 Jan 3;37(1):123-129. doi: 10.1016/j.vaccine.2018.11.022. Epub 2018 Nov 19. PMID:
30467064.
14. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey
R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE,
Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Safety and Immunogenicity of Two RNA-Based
Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906.
Epub 2020 Oct 14. PMID: 33053279; PMCID: PMC7583697.
15. Polack FP, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID:
33301246; PMCID: PMC7745181.
16. Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems
Science and Engineering (CSSE) at Johns Hopkins University. 2020, CDC, WHO, Khan T, Agnihotri K, Tripathi
A, Mukherjee S, Agnihotri N, Gupta G. COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak. Altern Ther
Health Med. 2020 Aug;26(S2):56-64. PMID: 32412918
17. https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov
18. https://ourworldindata.org
19. https://www.statista.com/statistics/1105914/coronavirus-death-rates-worldwide/
20. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available
weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi:
10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4. PMID: 32145363; PMCID: PMC7135139.
21. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-
19. Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4539-4547. doi: 10.26355/eurrev_202004_21038. PMID:
32373993.
22. Ibáñez S, Martínez O, Valenzuela F, Silva F, Valenzuela O. Hydroxychloroquine and chloroquine in COVID-
19: should they be used as standard therapy? Clin Rheumatol. 2020 Aug;39(8):2461-2465. doi:
10.1007/s10067-020-05202-4. Epub 2020 Jun 3. PMID: 32495226; PMCID: PMC7267470.
6. 6
23. N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020
Oct;20(10):1118. doi: 10.1016/S1473-3099(20)30296-6. Epub 2020 Apr 17. PMID: 32311322; PMCID:
PMC7164862.
24. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432. doi:
10.1136/bmj.m1432. PMID: 32269046.; Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM.
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
Ann Intern Med. 2020 Aug 18;173(4):287-296. doi: 10.7326/M20-2496. Epub 2020 May 27. PMID:
32459529.;
25. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and
hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. 2020 May;23(5):613-619. doi:
10.1111/1756-185X.13842. Epub 2020 Apr 27. PMID: 32281213; PMCID: PMC7262257.
26. Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn
Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5. Epub 2020
May 27. PMID: 32462282; PMCID: PMC7251046.
27. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary
regimen. J Antibiot (Tokyo). 2020 Sep;73(9):593-602. doi: 10.1038/s41429-020-0336-z. Epub 2020 Jun 12.
PMID: 32533071; PMCID: PMC7290143.
28. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ,
Leblebicioglu H. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol
Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w. PMID: 32473642; PMCID:
PMC7261036.
29. Shih RD, Johnson HM, Maki DG, Hennekens CH. Hydroxychloroquine for Coronavirus: The Urgent Need for
a Moratorium on Prescriptions. Am J Med. 2020 Sep;133(9):1007-1008. doi:
10.1016/j.amjmed.2020.05.005. Epub 2020 Jun 2. PMID: 32502485; PMCID: PMC7265864.
30. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J
Pharmacol. 2020 Nov 5;886:173451. doi: 10.1016/j.ejphar.2020.173451. Epub 2020 Aug 6. PMID: 32768505;
PMCID: PMC7406477.
31. Poon, L.L.M., Peiris, M. Emergence of a novel human coronavirus threatening human health. Nat Med 26,
317–319 (2020). https://doi.org/10.1038/s41591-020-0796-5
32. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States,
December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep 2021;70:95–99.
33. Harcourt J, Tamin A, Lu X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with
Coronavirus Disease, United States. Emerging Infectious Diseases. 2020;26(6):1266-1273.
doi:10.3201/eid2606.200516.
34. https://www.pfizer.com
35. IPAK Report 2021-1. 2021. Post-vaccination Death Causality Likely Given Temporal Distribution of Deaths
Following COVID19 Vaccinations. Interim results.
36. Tinari S. The EMA covid-19 data leak, and what it tells us about mRNA instability BMJ 2021; 372 :n627
doi:10.1136/bmj.n627
37. Ioannidis, J.P. (2021), Reconciling estimates of global spread and infection fatality rates of COVID-19: an
overview of systematic evaluations. Eur J Clin Invest. Accepted Author Manuscript e13554.
https://doi.org/10.1111/eci.13554
38. S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf
39. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and therapies against SARS-CoV-2
infection. Immunology. 2021 Jan;162(1):30-43. doi: 10.1111/imm.13262. Epub 2020 Oct 27. PMID:
32935333; PMCID: PMC7730020.
40. Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020
Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18. PMID: 32555388; PMCID:
PMC7442695.
41. Sun B, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes
Infect. 2020 Dec;9(1):940-948. doi: 10.1080/22221751.2020.1762515. PMID: 32357808; PMCID:
PMC7273175.
7. 7
42. Le Bert N, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15. PMID: 32668444.
43. Mateus J, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020
Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4. PMID: 32753554; PMCID:
PMC7574914.
44. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat
Rev Immunol. 2020 Nov;20(11):709-713. doi: 10.1038/s41577-020-00460-4. Epub 2020 Oct 6. PMID:
33024281; PMCID: PMC7537578.
45. Poorolajal J, Hooshmand E. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst
Rev. 2016 Jun 7;2016(6):CD008256. doi: 10.1002/14651858.CD008256.pub3. PMID: 27271960; PMCID:
PMC7154826.
46. Corbett, K.S., Edwards, D.K., Leist, S.R. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype
pathogen preparedness. Nature 586, 567–571 (2020). https://doi.org/10.1038/s41586-020-2622-0.
47. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.html
48. Noh J, Danuser G (2021) Estimation of the fraction of COVID-19 infected people in U.S. states and countries
worldwide. PLoS ONE 16(2): e0246772. https://doi.org/10.1371/journal.pone.0246772
49. Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell
Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates Clinical Infectious
Diseases, ciaa1491, https://doi.org/10.1093/cid/ciaa1491
50. Glenn D. Braunstein, Lori Schwartz, Pamela Hymel, Jonathan Fielding. False Positive Results With SARS-CoV-
2 RT-PCR Tests and How to Evaluate a RT-PCR-Positive Test for the Possibility of a False Positive Result.
Journal of Occupational & Environmental Medicine, Volume Publish Ahead of Print, 1 January 2021
51. Karen A Alroy, et al., Population-Based Estimates of Coronavirus Disease 2019 (COVID-19)–like Illness,
COVID-19 Illness, and Rates of Case Ascertainment, Hospitalizations, and Deaths—Noninstitutionalized
New York City Residents, March–April 2020, Clinical Infectious Diseases, 2021; ciab038,
https://doi.org/10.1093/cid/ciab038
52. https://github.com/dancarmoz/israel_moh_covid_dashboard_data
53. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity
54. Chen L, Liu P, Gao H, Sun B, Chao D, Wang F, Zhu Y, Hedenstierna G, Wang CG. Inhalation of nitric oxide in
the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004 Nov
15;39(10):1531-5. doi: 10.1086/425357. Epub 2004 Oct 22. PMID: 15546092; PMCID: PMC7107896.
55. https://clinicaltrials.gov/ct2/show/NCT04358588
56. Yuyang Lei et al., SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
Originally published 31 Mar 2021 in Circulation Research
https://doi.org/10.1161/CIRCRESAHA.121.318902
57. Irani RA, Xia Y. Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol. 2011
Jan;31(1):47-58. doi: 10.1016/j.semnephrol.2010.10.005. PMID: 21266264; PMCID: PMC3275085.]
58. Line Malha et al., Renin-Angiotensin-Aldosterone Profiles in Pregnant Women with Chronic Hypertension.
Hypertension. Originally published 25 Jun 2018. https://doi.org/10.1161/HYPERTENSION
AHA.118.10854Hypertension. 2018;72:417–424
59. Rasha F, Ramalingam L, Gollahon L, Rahman RL, Rahman SM, Menikdiwela K, Moustaid-Moussa N.
Mechanisms linking the renin-angiotensin system, obesity, and breast cancer. Endocr Relat Cancer. 2019
Dec 1;26(12):R653-R672. doi: 10.1530/ERC-19-0314. PMID: 31525726.